FDA Approval Alert: The Need-to-Know | Mirdametinib in Adult/Pediatric NF1-PN

In February 2025, the FDA mirdametinib as a treatment for pediatric and adult patients 2 years and older with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN) not amenable to complete resection.

Findings from the phase 2b ReNeu trial show significant pain relief with mirdametinib in adult and pediatric patients with NF1-PN.
Objective Data Highlight Substantial Benefits With Mirdametinib in NF1-PN
Video
Feb 12, 2025 2:00 PM
Findings from the phase 2b ReNeu trial show significant pain relief with mirdametinib in adult and pediatric patients with NF1-PN.
The dispersible tablet formulation of mirdametinib may offer convenience to patients with NF1-PN and difficulty with swallowing pills.
Mirdametinib Approval Brings Tumor Shrinkage and QOL Advantages to NF1-PN
Video
Feb 11, 2025 11:00 PM
The dispersible tablet formulation of mirdametinib may offer convenience to patients with NF1-PN and difficulty with swallowing pills.
Findings from the phase 2b ReNeu trial support the approval of mirdametinib for patients with neurofibromatosis type 1-associated plexiform neurofibromas.
FDA Approves Mirdametinib in Adult/Pediatric NF1-PN
Article
Feb 11, 2025 9:02 PM
Findings from the phase 2b ReNeu trial support the approval of mirdametinib for patients with neurofibromatosis type 1-associated plexiform neurofibromas.